Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
View Regular
Stephen V Liu, MD Profile picture
Stephen V Liu, MD
@StephenVLiu
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Co-Host @IASLC Podcast; Chair #TexasLung25; #HereWeGo #LetsGoBucs

Sep 11, 2022, 5 tweets

Dr. @marinagarassino presents 5-year efficacy and safety update of KEYNOTE-189 (1L carboplatin plus pemetrexed +- pembrolizumab in non-squamous NSCLC) #ESMO22

KEYNOTE 189 is our SOC and has shown a consistent benefit including improving OS even with a crossover rate of 57%. #ESMO22

KEYNOTE 189 shows sustained OS benefit with longer follow up and a 5y OS rate of 18.4% with an OS HR of 0.60. Better PFS and OS also observed. Benefit across PDL1 strata. No new safety signals . #ESMO22

Here are data from patients who completed the 35 planned cycles of pembrolizumab on KEYNOTE 189. In that group, RR 86% and mDOR 58m with a 72% 3y OS rate. Note 40% alive without PD or subsequent therapy. Looking forward to more details on this group. #ESMO22

Longer follow up confirms survival benefit of chemo-immunotherapy in NSCLC. Important update from #ESMO22 by @marinagarassino

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling